NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 12/01/2025 at 14:30, 8 months 13 days ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
NanoViricides, Inc. signs MSA with regulatory consultant firm for orphan drug strategy development for NV-387, a broad-spectrum antiviral with potential against Smallpox, Measles, and more

NanoViricides NV-387 Antiviral Orphan Drug Drug Strategy
BRIEF

published on 11/17/2025 at 14:35, 8 months 27 days ago

NanoViricides renforce sa situation financière grâce à un financement récent

NV-387 Financement Essais Cliniques Situation Financière Médicament Antiviral
BRIEF

published on 11/17/2025 at 14:35, 8 months 27 days ago

NanoViricides Fortifies Fiscal Position with Recent Funding

NV-387 Financial Position Funding Clinical Trials Antiviral Drug
PRESS RELEASE

published on 11/17/2025 at 14:30, 8 months 27 days ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. files Form 10-Q for Q3 2025 with SEC, presents NV-387 as broad-spectrum antiviral drug addressing unmet medical needs. Company strengthens financial position with recent financings

NanoViricides NV-387 Financings Form 10-Q Antiviral Drug
BRIEF

published on 11/14/2025 at 14:35, 9 months ago

NanoViricides Highlights NV-387 at Pharma Partnering Summit 2025

NanoViricides NV-387 Antiviral Drugs Influenza H3N2 Pharma Partnering Summit 2025
BRIEF

published on 11/14/2025 at 14:35, 9 months ago

NanoViricides présente le NV-387 au Pharma Partnering Summit 2025

NanoViricides NV-387 Médicaments Antiviraux Grippe H3N2 Sommet Des Partenariats Pharmaceutiques 2025
PRESS RELEASE

published on 11/14/2025 at 14:30, 9 months ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
NanoViricides, Inc. to present NV-387, a revolutionary broad-spectrum antiviral drug, at Pharma Partnering Summit 2025. NV-387 mimics virus features to combat viral infections effectively

NanoViricides NV-387 Antiviral Drug Clinical Stage Pharma Partnering Summit 2025
BRIEF

published on 11/12/2025 at 23:06, 9 months 2 days ago

NanoViricides Finalizes $6 Million Funding Round

Private Placement Warrants SEC Compliance Direct Offering Antiviral Development
BRIEF

published on 11/12/2025 at 23:06, 9 months 2 days ago

NanoViricides finalise une levée de fonds de 6 millions de dollars

Placement Privé Mandats Offre Directe Conformité SEC Développement Antiviral
PRESS RELEASE

published on 11/12/2025 at 23:01, 9 months 2 days ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces closing of $6 million offering with healthcare investor. Proceeds for working capital. AGP/Alliance acted as placement agent

NanoViricides Securities Purchase Agreement Registered Direct Offering Healthcare Investor AGP/Alliance

Published on 08/15/2026 at 00:50, 6 hours 13 minutes ago

Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 6 hours 48 minutes ago

Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 7 hours 18 minutes ago

AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 7 hours 38 minutes ago

NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 8 hours 3 minutes ago

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE

Published on 08/14/2026 at 18:29, 12 hours 34 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:29, 12 hours 34 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:15, 12 hours 48 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 14 hours 57 minutes ago

GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:29, 15 hours 33 minutes ago

Tradegate AG publishes its half-year report

View all EQS

Published on 08/13/2026 at 18:00, 1 day 13 hours ago

Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 3 days 13 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days 13 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days 13 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days 13 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE

News